155 related articles for article (PubMed ID: 30570930)
1. [Chloroquine retinopathy].
Nguyen AL; Tan AN; Lavrijsen APM
Ned Tijdschr Geneeskd; 2018 Dec; 163():. PubMed ID: 30570930
[TBL] [Abstract][Full Text] [Related]
2. [Safety management of the treatment with antimalarial drugs in rheumatology. Interdisciplinary recommendations based on a systematic literature search].
Fiehn C; Ness T; Weseloh C; Specker C; Hadjiski D; Detert J; Krüger K;
Z Rheumatol; 2020 Mar; 79(2):186-194. PubMed ID: 32095892
[TBL] [Abstract][Full Text] [Related]
3. Identification of new risk factors for hydroxychloroquine and chloroquine retinopathy in systemic lupus erythematosus patients.
Trefond L; Lhote R; Mathian A; de Chambrun MP; Pha M; Hie M; Miyara M; Papo M; Moyon Q; Taieb D; Saade S; Salem TB; Haroche J; Chasset F; Aubart FC; Zahr N; Amoura Z
Semin Arthritis Rheum; 2024 Jun; 66():152417. PubMed ID: 38394986
[TBL] [Abstract][Full Text] [Related]
4. Quantitative Fundus Autofluorescence in Systemic Chloroquine/Hydroxychloroquine Therapy: One Year Follow-Up.
Radun V; Berlin A; Tarau IS; Kleefeldt N; Reichel C; Hillenkamp J; Holz FG; Sloan KR; Saßmannshausen M; Ach T
Transl Vis Sci Technol; 2023 Jul; 12(7):8. PubMed ID: 37418250
[TBL] [Abstract][Full Text] [Related]
5. Quantitative Fundus Autofluorescence in Systemic Chloroquine/Hydroxychloroquine Therapy.
Reichel C; Berlin A; Radun V; Tarau IS; Hillenkamp J; Kleefeldt N; Sloan KR; Ach T
Transl Vis Sci Technol; 2020 Aug; 9(9):42. PubMed ID: 32934892
[TBL] [Abstract][Full Text] [Related]
6. Long-term effectiveness of antimalarial drugs in rheumatic diseases.
Aviña-Zubieta JA; Galindo-Rodriguez G; Newman S; Suarez-Almazor ME; Russell AS
Ann Rheum Dis; 1998 Oct; 57(10):582-7. PubMed ID: 9893568
[TBL] [Abstract][Full Text] [Related]
7. Chloroquine-induced bull's eye maculopathy in rheumatoid arthritis: related to disease duration?
Shinjo SK; Maia OO; Tizziani VA; Morita C; Kochen JA; Takahashi WY; Laurindo IM
Clin Rheumatol; 2007 Aug; 26(8):1248-53. PubMed ID: 17264974
[TBL] [Abstract][Full Text] [Related]
8. Chloroquine and hydroxychloroquine retinopathy-related risk factors in a Turkish cohort.
Yaylali SA; Sadigov F; Erbil H; Ekinci A; Akcakaya AA
Int Ophthalmol; 2013 Dec; 33(6):627-34. PubMed ID: 23456514
[TBL] [Abstract][Full Text] [Related]
9. Hydroxychloroquine-induced hyperpigmentation of the skin and bull's-eye maculopathy in rheumatic patients: a case report and literature review.
Peng JP; Yang XY; Luo F; Yuan XM; Xiong H; Ma WK; Yao XM
Front Immunol; 2024; 15():1383343. PubMed ID: 38660312
[TBL] [Abstract][Full Text] [Related]
10. Screening for chloroquine maculopathy in populations with uncertain reliability in outcomes of automatic visual field testing.
Kunavisarut P; Chavengsaksongkram P; Rothova A; Pathanapitoon K
Indian J Ophthalmol; 2016 Oct; 64(10):710-714. PubMed ID: 27905330
[TBL] [Abstract][Full Text] [Related]
11. Early onset monocular hydroxychloroquine maculopathy in a systemic lupus erythematosus patient with history of central retinal artery occlusion: a case report.
Ameen Ismail A; Sadek SH; Hatata RM
BMC Ophthalmol; 2022 Nov; 22(1):434. PubMed ID: 36376841
[TBL] [Abstract][Full Text] [Related]
12. [Chloroquine-induced bull's eye maculopathy without electrophysiologic changes].
Cursiefen C; Grunert U; Jünemann A
Klin Monbl Augenheilkd; 1997 Jun; 210(6):400-1. PubMed ID: 9333669
[TBL] [Abstract][Full Text] [Related]
13. Safety management in treatment with antimalarials in rheumatology. Interdisciplinary recommendations on the basis of a systematic literature review.
Fiehn C; Ness T; Weseloh C; Specker C; Hadjiski D; Detert J; Krüger K;
Z Rheumatol; 2021 Feb; 80(Suppl 1):1-9. PubMed ID: 32236844
[TBL] [Abstract][Full Text] [Related]
14. Retinal toxicity associated with chronic exposure to hydroxychloroquine and its ocular screening. Review.
Geamănu Pancă A; Popa-Cherecheanu A; Marinescu B; Geamănu CD; Voinea LM
J Med Life; 2014 Sep; 7(3):322-6. PubMed ID: 25408748
[TBL] [Abstract][Full Text] [Related]
15. Use of microperimetry to evaluate hydroxychloroquine and chloroquine retinal toxicity.
Martínez-Costa L; Victoria Ibañez M; Murcia-Bello C; Epifanio I; Verdejo-Gimeno C; Beltrán-Catalán E; Marco-Ventura P
Can J Ophthalmol; 2013 Oct; 48(5):400-5. PubMed ID: 24093187
[TBL] [Abstract][Full Text] [Related]
16. Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study.
Mittal L; Zhang L; Feng R; Werth VP
J Am Acad Dermatol; 2018 Jan; 78(1):100-106.e1. PubMed ID: 28989103
[TBL] [Abstract][Full Text] [Related]
17. Retinal Complications in Patients with Systemic Lupus Erythematosus Treated with Antimalarial Drugs.
Mukwikwi ER; Pineau CA; Vinet E; Clarke AE; Nashi E; Kalache F; Grenier LP; Bernatsky S
J Rheumatol; 2020 Apr; 47(4):553-556. PubMed ID: 31474597
[TBL] [Abstract][Full Text] [Related]
18. Hydroxychloroquine and chloroquine retinopathy: a systematic review evaluating the multifocal electroretinogram as a screening test.
Tsang AC; Ahmadi Pirshahid S; Virgili G; Gottlieb CC; Hamilton J; Coupland SG
Ophthalmology; 2015 Jun; 122(6):1239-1251.e4. PubMed ID: 25824328
[TBL] [Abstract][Full Text] [Related]
19. Hydroxychloroquine retinopathy.
Yusuf IH; Sharma S; Luqmani R; Downes SM
Eye (Lond); 2017 Jun; 31(6):828-845. PubMed ID: 28282061
[TBL] [Abstract][Full Text] [Related]
20. Skin and ophthalmic complications of chloroquine and hydroxychloroquine in patients with rheumatoid arthritis and systemic lupus erythematous.
Zamani B; Hasan-Abad AM; Rafizadeh SM; Akbari H; Motedayyen H
J Immunoassay Immunochem; 2024 May; 45(3):178-188. PubMed ID: 38722204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
